Phaseline

Companies › TuHURA Biosciences

TuHURA Biosciences: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IFx-Hu2.0
Innate immune agonist
–Phase 2Advanced Or Metastatic Merkel Cell CarcinomaMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06947928IFx-Hu2.0Phase 2Advanced Or Metastatic Merkel Cell CarcinomaOncologyMar 2027
NCT06940440IFx-Hu2.0Phase 1Advanced Or Metastatic Merkel Cell CarcinomaOncologyApr 2027

From the company's SEC filings

Cash of $1m on 2026-06-30; operating cash outflow about $26m a year; runway about 0 months at that burn, to Jul 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Oncolytics Biotech Cardiff Oncology Actuate Therapeutics Inhibrx Biosciences Genelux

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.